WHAT IS CLAIMED IS:

[0132]

1. A compound according to the formula



and the pharmaceutically acceptable salts thereof,

wherein

each Z is independently N or C(R^1), with the proviso that no more than 2 Z's in any one aromatic ring are N;

Y is O, N, or S;

Q is N or C(R^1), with the proviso that Q is C(R^1) when Y is N;

Ar is an unsubstituted or substituted aromatic or heteroaromatic 5- or 6-member ring;

each R^1 is independently H, halogen, OH, or a C_1 to C_{12} alkyl heteroalkyl moiety;

each R^2 is independently H or a C_1 to C_{18} alkyl or heteroalkyl moiety or the two R^2's taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroalkyl 5 to 7 member ring;

and

R^3 is H or a C_1 to C_6 alkyl moiety;

with the proviso that at least one group R^1, R^2, or R^3 contains an alkyl amine group or a quaternary nitrogen group.

2. A compound according to claim 1, wherein at least one group R^2 contains an alkyl amine group.

3. A compound according to claim 1 or 2, wherein



is selected from the group consisting of






and


wherein R^1 is H or CH_3.

4. A compound according to claim 1 or 2, wherein



is selected from the group consisting of






and


5. A compound according to claim 1 or 2, wherein



is selected from the group consisting of



and


wherein R^1 is H or CH_3.

6. A compound according to claim 1 or 2, wherein



is selected from the group consisting of



7. A compound according to claim 1 or 2, wherein



is selected from the group consisting of



wherein one of X^1, X^2, and X^3 is a ring vertex selected from the group consisting of -O-, -S-, and $-NR^8$-, and the other two of X^1, X^2, and X^3 are ring vertices selected from the group consisting of =N- and $=CR^7$-; each R^7 is independently H, F, Cl, Br, I, CN, OH, NO_2, NH_2, a substituted or unsubstituted (C_1-C_{12})alkyl group, a substituted or unsubstituted (C_1-C_{12})alkoxy group, or a substituted or unsubstituted (C_1-C_{12})heteroalkyl group; and R^8 is H, a substituted or unsubstituted (C_1-C_{12})alkyl group, or a substituted or unsubstituted (C_1-C_{12})heteroalkyl group.

8. A compound according to claim 1 or 2, wherein

is selected from the group consisting of



and


9. A compound according to claim 1 or 2, wherein R^3 is H.

10. A compound according to a formula selected from the group consisting of

















and


and the pharmaceutically acceptable salts thereof,

wherein each R^2 is independently H or a C_1 to C_{18} alkyl or heteroalkyl moiety or the two R^2's taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroalkyl 5 to 7 member ring; at least one group R^2 containing an alkyl amine group.

11. A compound according to claim 1, 2 or 10, wherein $N(R^2)_2$ is selected from the group consisting of



















and


12. A compound according to claim 1, having a minimum inhibitory concentration of 4 μg/mL or less against at least one of *Staphylococcus aureus* (ATCC 27660), *Streptococcus pneumoniae* (ATCC 51422), and *Enterococcus faecium* (ATCC 51559).

13. A method of treating a bacterial infection in a mammal, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, 2, or 10.

14. A method according to claim 13, wherein the bacterial infection is an infection by drug resistant bacteria.

15. A method according to claim 14, wherein the drug resistant bacteria is MRSA, PRSP, or VRE.

16. The use of a compound according to claim 1, 2, or 8 for the preparation of a medicament for the treatment of a bacterial infection in a mammal.